Anti-influenza (M2 and NA) Drugs
|
|
- Cornelius Welch
- 6 years ago
- Views:
Transcription
1 Anti-influenza (M2 and NA) Drugs Alan J. Hay MRC National Institute for Medical Research, London Summer School on Influenza Siena 1-5 August 2011
2 Antiviral drugs licensed for use against influenza M2 (Flu A) inhibitors - amantadine (oral) - rimantadine (oral) NA inhibitors - zanamivir (inhaled; [i.v.]) - [laninamivir (inhaled) Japan)] - oseltamivir (oral) - [peramivir (i.v.) Japan)] HA fusion inhibitors - [arbidol (oral) Russia]
3 Control of Influenza Vaccines Vaccination most effective way of combatting seasonal flu (and pandemic flu - when available) Antivirals Early in pandemic situation (stockpile against H5N1 threat) Prophylaxis % effective in prevention of infection (equivalent to vaccination) Treatment reduce duration and severity of disease. Short acute infection need to be administer early (within 48 hr of onset of symptoms) (special hotline in UK for 2009 pandemic). Prolonged replication (severe disease; immunocompromised patients) Resistance - selection during treatment - is a major consideration/limitation in their use - emergence during evolution of virus Co-circulation of drug-sensitive and -resistant viruses have complicated recommendations for antiviral use in recent years
4
5 Control of Influenza Vaccines Vaccination most effective way of combatting seasonal flu (and pandemic flu - when available) Antivirals Early in pandemic situation (stockpile against H5N1 threat) Prophylaxis % effective in prevention of infection (equivalent to vaccination) Treatment reduce duration and severity of disease. Short acute infection need to be administer early (within 48 hr of onset of symptoms) (special hotline in UK for 2009 pandemic). Prolonged replication (severe disease; immunocompromised patients) Resistance - selection during treatment - is a major consideration/limitation in their use - emergence during evolution of virus Co-circulation of drug-sensitive and -resistant viruses have complicated recommendations for antiviral use in recent years
6 Sites of action of antivirals Arbidol
7 Amantadine identified and developed in 1960s; target and mechanism of action not identified till 1980s Effective against influenza A (M2), but not influenza B (BM2) viruses Used as anti-parkinsons agent (concerns about side-effects) Resistance! Limited use of the drugs (amantadine used in 1968 pandemic) Rimantadine more effective (less side-effects) than amantadine drug of choice, but less widely licensed
8 Amantadine resistance mutations in the M2 proton channel FA T N E Emerge frequently in vitro; in epidemic H3N2 and H1N1 viruses Similar to wt in infectivity, virulence and transmissibility Well-defined mutations (residues 26, 27, 30, 31 or 34) - correlate with resistance in vitro and in vivo Screen for resistance by sequencing M gene (pyrosequencing)
9
10 M2 activities inhibited by amantadine Virus uncoating HP avian influenza H5 and H7 HAs are cleaved during transport through the trans Golgi Network (TGN) and become susceptible to low ph-induced conformation change transport of native HA requires active M2 to reduce the acidity of the TGN - increases sensitivity of virus production to amantadine in vitro
11 Locations of Val27Ala and Ser31Asn mutations in the M2 channel (tetramer) which causes resistance to amantadine
12 M2 forms a proton-selective channel specifically inhibited by amantadine N I MR Electrophysiology (patch-clamp) M2 forms a proton-selective channel Proton currents specifically inhibited by amantadine/rimantadine Amantadine-resistant mutations abrogate inhibition basis of clinical activity
13 Crystal structure of the transmembrane pore of the M2 proton channel and interaction of amantadine Stouffer et al, 2008
14 ph dependent changes in M2 structure in relation to proton transport and drug interaction His37 Trp41 High ph Channel closed Greater drug access Binds irreversibly Low ph Channel conducting More restricted drug access
15 Comparative structures of wt and mutant M2 channels (NMR) [Pielak and Chou, 2010] Reduced drug affinity Drug binds externally Low amantadine affinity Fast reversible inhibition Slow irreversible inhibition Slow reversible inhibition [S. Tokar] ph dependent High affinity for closed form ph independent
16 Preferable docking poses for aminoadamantane derivatives Amantadine (1) Rimantadine (20) Alkyl amantadines ( ) Spiropiperidine (0.8) Spiropyrrolidine (0.3) Cyclic rimantadines ( ) [Eleftheratos et al, 2010] (Binding affinities relative to amantadine)
17 Emergence of amantadine resistance in human and animal viruses Pre 1980 s - low incidence; approx. 1% Mid 1980 s - European swine viruses (sporadic human cases) avian H5N1, H9N2 (SE Asia) avian H5N1 clades 1; human cases H5N3 (SE Asia) H7N2 (N America) human H3N2 (China/Hong Kong - worldwide) human H1N1 emergent variant (clade 2C) pandemic H1N1 2009
18 Emergence of amantadine resistance in human and animal viruses Pre 1980 s - low incidence; approx. 1% Mid 1980 s - European swine viruses (sporadic human cases) avian H5N1, H9N2 (SE Asia) avian H5N1 clades 1; human cases H5N3 (SE Asia) H7N2 (N America) human H3N2 (China/Hong Kong - worldwide) human H1N1 emergent variant (clade 2C) pandemic H1N1 2009
19 M genes of H5N1 viruses amantadine resistance (Most sensitive) (Most sensitive) (Most resistant) (All resistant)
20 Emergence of amantadine resistance in human and animal viruses Pre 1980 s - low incidence; approx. 1% Mid 1980 s - European swine viruses (sporadic human cases) avian H5N1, H9N2 (SE Asia) avian H5N1 clades 1; human cases H5N3 (SE Asia) H7N2 (N America) human H3N2 (China/Hong Kong - worldwide) human H1N1 emergent variant (clade 2C) pandemic H1N1 2009
21 Emergence of amantadine-resistant H3N2 viruses, Bright et al 2005
22 Changes in amantadine resistance of H3N2 viruses HA genes Brisbane/10/ resistant M genes Wisconsin/67/ resistant ~50% resistant California/7/ sensitive
23 Emergence of amantadine resistance in human and animal viruses Pre 1980 s - low incidence; approx. 1% Mid 1980 s - European swine viruses (sporadic human cases) avian H5N1, H9N2 (SE Asia) avian H5N1 clades 1; human cases H5N3 (SE Asia) H7N2 (N America) human H3N2 (China/Hong Kong - worldwide) human H1N1 emergent variant (clade 2C) pandemic H1N1 2009
24 Recent changes in amantadine resistance of H1N1 viruses HA genes 2C M genes 2B 2B 2C
25 Emergence of amantadine resistance in human and animal viruses Pre 1980 s - low incidence; approx. 1% Mid 1980 s - European swine viruses (sporadic human cases) avian H5N1, H9N2 (SE Asia) avian H5N1 clades 1; human cases H5N3 (SE Asia) H7N2 (N America) human H3N2 (China/Hong Kong - worldwide) human H1N1 emergent variant (clade 2C) pandemic H1N1 2009
26 Origin of amantadine resistance (M2 S31N) of pandemic H1N1 viruses
27 Resistance to amantadine/rimantadine Human viruses all resistant? - H3N2 - pandemic H1N1 - B Avian - H5N1 clades associated with human infection Swine - Eurasian H1N1, H3N2 - Pandemic H1N1 Amantadine/rimantadine currently of little use Attempts to develop alternative inhibitors with broader spectrum of activity against M2 of influenza B as well as amantadine-resistant A viruses continue
28
29 Structure-based Drug Design DANA low M Oseltamivir low nm
30 Inhibitors of influenza A and B neuraminidases Inhaled Oral (prodrug) Intravenous The guanidino group of zanamivir and the ethylpropoxy group of oseltamivir, both present in peramivir, are highlighted. Potential complementary resistance profiles of oseltamivir and zanamivir
31 Laninamivir long-lasting derivative of zanamivir (single administration) 3-O-octanoyl prodrug Laninamivir
32 Interaction of the active moieties of inhibitors with NA Guanidino group binds to a pocket formed by acidic residues Glu119, Asp151 and Glu227 Ethylpropoxy group binds a hydrophobic pocket exposed by reorientation of Glu276
33 Mutations affecting oseltamivir binding to the hydrophobic pocket I222R (N1) Deletion
34 Type and subtype specificity of resistance mutations and complementarity of drugs
35 Emergence of resistance to zanamivir and oseltamivir Clinical trials Zanamivir low (?) Oseltamivir adults: 0.3%(4/1228) children: 4%(17/421) Oseltamivir treatment studies Japanese children - H1N1: 16%(7/43) (Ward et al,2005) - H3N2: 18%(9/50) (Kiso et al, 2004) - B : 1.4%(1/74) (Hatakeyama et al, 2007) Japanese(untreated) B: 1.7%(7/422) (Hatakeyama et al) H5N1-infected patients: 25%(2/8) (de Jong et al, 2005) Seasonal H1N1 viruses (Late ) Emergence and worldwide spread of oseltamivir resistance (H275Y) almost 100% by mid 2008 (in e.g. South Africa, Australia) Pandemic H1N1 Sporadic cases of resistance (H275Y) to oseltamivir (sensitive to zanamivir) 1% of >6000 isolates in Japan. Some from untreated patients transmission? Associated with typical illness.
36 Emergence of resistance to zanamivir and oseltamivir Clinical trials Zanamivir low (?) Oseltamivir adults: 0.3%(4/1228) children: 4%(17/421) Oseltamivir treatment Japanese children - H1N1: 16%(7/43) (Ward et al,2005) - H3N2: 18%(9/50) (Kiso et al, 2004) - B : 1.4%(1/74) (Hatakeyama et al, 2007) Japanese(untreated) B: 1.7%(7/422) (Hatakeyama et al) H5N1-infected patients: 25%(2/8) (de Jong et al, 2005) Seasonal H1N1 viruses (Late ) Emergence and worldwide spread of oseltamivir resistance (H275Y) almost 100% by mid 2008 (in e.g. South Africa, Australia) Pandemic H1N1 Sporadic cases of resistance (H275Y) to oseltamivir (sensitive to zanamivir)
37 Effect of Oseltamivir Treatment on Virus Load in H5N1 Patients [arrows indicate resistant virus (H274Y)] Died Survived M. de Jong et al. N. Eng. J. Med. 2005
38 Emergence of resistance to zanamivir and oseltamivir Clinical trials Zanamivir low (?) Oseltamivir adults: 0.3%(4/1228) children: 4%(17/421) Oseltamivir treatment Japanese children - H1N1: 16%(7/43) (Ward et al,2005) - H3N2: 18%(9/50) (Kiso et al, 2004) - B : 1.4%(1/74) (Hatakeyama et al, 2007) Japanese(untreated) B: 1.7%(7/422) (Hatakeyama et al) H5N1-infected patients: 25%(2/8) (de Jong et al, 2005) Seasonal H1N1 viruses (Late ) Emergence and worldwide spread of oseltamivir resistance (H275Y) almost 100% by mid 2008 (in e.g. South Africa, Australia) Pandemic H1N1 Sporadic cases of resistance (H275Y) to oseltamivir (sensitive to zanamivir)
39 Genetic drift of H1 HA single substitutions cause major antigenic change
40 Emergence of oseltamivir-resistant seasonal H1N1 viruses during (Amantadine-resistant)
41 Genetic differences which correlate with H275Y resistance mutation in clade 2B ( European ) NA D354G (reversion) PB2 P453S PB1-F2 L30R/E22G (truncated, 57 amino acids)
42 Emergence of oseltamivir-resistant seasonal H1N1 viruses during (Amantadine resistant)
43 Proximity of recent amino acid changes in NA of H1N1 viruses to the catalytic site
44 Correlation between Km of NA activity (substrate affinity) and asparagine (N) or aspartic acid (D) at position 344 H1N1 Virus Km (µm) Ki (nm) Amino acid position Clade 2B Clade 2C Clade 2A Clade 1 Oseltamivir Zanamivir A/Dnipro/117/08 * 24.9 ± * 0.44 Q K Y N G A/England/26/08 * 31 ± 4 86 * 0.51 Q K Y N G A/Paris/341/07 * 21.2 ± * 0.27 Q K Y N G A/Norway/1735/07 * 11.1 ± * 0.18 Q K Y N G A/Norway/1758/ ± Q K H N D A/Kiev/245/ ± Q K H N D A/Yokohama/35/08 * 31.8 ± * 0.66 Q K Y N D A/Yokohama/22/08 * 30.8 ± * 0.59 Q K Y N D A/England/654/07 * 28 ± * 0.31 Q K Y N D A/England/545/07 17 ± Q K H N D A/Paris/194/ ± Q K H N D A/Brisbane/59/ ± Q K H N D A/Slovenia/246/ ± Q G H N G A/Hong Kong/2652/06 15 ± Q G H N G A/St.Petersburg/10/ ± Q G H N G A/England/594/06 * 138 ± * 1.36 Q R Y D D A/England/593/06 89 ± Q R H D D A/St.Petersburg/96/07 62 ± Q R H D D A/Fukushima/141/06 76 ± R G H D G A/Solomon Islands/3/ ± R G H D G A/Egypt/39/ ± R G H D G A/England/493/ ± R G H D G A/England/494/06 * 133 ± * 1.34 R G Y D G A/Thessaloniki/24/ ± R G H D G A/Morocco/69/ ± Q G H N G A/Iceland/1/ ± Q G H N G A/Lisbon/5/00 18 ± Q G H N G A/New Caledonia/20/ ± R G H D G A/Ostrava/801/ ± Q G H D G A/Beijing/262/95 83 ± R G H D G A/Durban/113/97 85 ± Q G H D G A/Bayern/7/ ± Q G H N G A/Texas/36/ ± R G H D G A/Brazil/11/ ± Q G H D G * Oseltamivir Resistant Viruses Km < 35 µm (6 33µM) Km > 35µM (43 214µM) Increased activity of NA associated with D344N substitution - compensates for reduced activity due to H275Y resistance mutation?
45 Effects of the H275Y mutation on the location of Glu 276 of N1 of A/Vietnam/1203/04(H5N1) in complex with with oseltamivir or zanamivir Reduction in binding affinity: ~300 fold Reduction in binding affinity: 2 fold Wild type (yellow); H274Y mutant (green)
46 Locations of recent amino acid changes in the NAs of seasonal H1N1 viruses relative to the catalytic site and H275Y oseltamivir-resistant mutation Compensatory mutations: D344N - increase in NA activity R222Q + V234M increase in cell surface expression of NA (Bloom et al, 2010) H275Y adaptive change?; resistance to oseltamivir simply coincidental
47
48 Emergence of resistance to zanamivir and oseltamivir Clinical trials Zanamivir low (?) Oseltamivir adults: 0.3%(4/1228) children: 4%(17/421) Oseltamivir treatment studies Japanese children - H1N1: 16%(7/43) (Ward et al,2005) - H3N2: 18%(9/50) (Kiso et al, 2004) - B : 1.4%(1/74) (Hatakeyama et al, 2007) Japanese(untreated) B: 1.7%(7/422) (Hatakeyama et al) H5N1-infected patients: 25%(2/8) (de Jong et al, 2005) Seasonal H1N1 viruses (Late ) Emergence and worldwide spread of oseltamivir resistance (H275Y) almost 100% by mid 2008 (in e.g. South Africa, Australia) Pandemic H1N1 Sporadic cases of resistance (H275Y;[ I223R]) to oseltamivir (sensitive to zanamivir) 1% of >6000 isolates in Japan. Some from untreated patients transmission? 4 of 8 patients infected by transmission of resistant virus in haematology unit in UK No transmission to the wider community.
49 Oseltamivir-resistant pandemic H1N1 viruses: sporadic (~340 cases to January 2011) (Effect of H275Y on transmission in animals contradictory data)
50 Effects of anti-na drugs on infection Inhibits receptor destroying activity Inhibits receptor binding by D151G mutants - selected in cell culture (clinical significance?) Reduces synergistic bacterial infection prevents exposure of cryptic receptors
51 Location of residue 151 (D151G/N) at the edge of the catalytic site of NA Sialic acid Substitution of aspartic acid(d) 151 by glycine(g) (or asparagine(n)) causes: No change in enzyme activity of NA NA to bind additional receptors, different from HA, and refractory to enzymatic cleavage Residue 151 important in restricting interaction with sialic acid receptors, to match cleavage activity and HA binding Natural significance (low level in clinical specimens)? [Lin et al, 2010]
52 Effects of anti-na drugs on infection Inhibits receptor destroying activity Inhibits receptor binding by D151G mutants (clinical significance?) Reduces synergistic bacterial infection (mice, ferrets) prevents exposure of cryptic receptors
53 Oseltamivir reduces secondary infection by S. pneumoniae McCullers and Bartmess. JID 187:1000; 2003
54 Anti-NA antivirals Only antivirals widely used Resistance major concern in relation to use (especially oseltamivir) Resistance to zanamivir less frequent Complementary resistance profiles Zanamivir (laninamivir) effective against oseltamivir-resistant viruses
55
56 Activation of HA by proteolytic cleavage and membrane fusion at low ph ph ~5 Site of cleavage Low ph triggers: - conformational transition - promotes membrane fusion Proteolytic cleavage activates infectivity
57 Inhibitors of HA Fusion (tend to be subtype-specific) Tert butyl hydroquinone (TBHQ) (H3) [Bodian et al, 1993] Qinolizidines (BMY 27709) (H1 + H2) [Luo et al 1996] Substituted piperidines (H1 + H2) [Plotch et al, 1999] Arbidol (effective against influenza A and B) [Glushkov et al, 1992] Licensed in Russia in 1990 mechanism of action?
58 Arbidol causes increase in acid stability of HA of wt (A) - abrogated by Arbidol-resistant mutation (HA2 K51N) (B) Wild type HA2 K51N mutant Control Arbidol Conformational change occurs at 0.2 ph units lower in presence of Arbidol Leneva et al 2009
59 Arbidol-resistant mutations (in vitro) cause increase in ph of the conformational change in HA (A) and haemolysis (B) by the H7 virus (i.e. reduce acid stability to counteract the stabilising effect of Arbidol A. Conformational change determined by reactivity with native- and low phspecific antibodies B. Haemolysis Mutant Wild type Leneva et al 2009
60 Locations of Arbidol-resistance mutations - putative binding site Leneva et al 2009
61 Binding of TBHQ in the crystal structure of X-31 H3 HA Russell et al 2008 Structural differences explain the subtype-specificity of TBHQ inhibition of H3 but not H1 TBHQ binds to each subunit of the HA trimer Arbidol binds in a similar location in H3 HA what is the basis for its broader specificity against viruses with group 1 (H1) and group 2 (H3) HAs? No in vivo Arbidol-resistant mutants identified Is stabilisation of the HA the basis of its in vivo antiviral action?
62 Inhibition of influenza replication X XArbidol
63 Antiviral drugs licensed for use against influenza A M2 inhibitors - amantadine - rimantadine NA inhibitors - zanamivir (inhaled) - laninamivir (inhaled) - oseltamivir (oral) - peramivir (i.v.) HA fusion inhibitors arbidol (Russia)
64
65 NIMR (Mill Hill) Acknowledgements WHO Flu Centre John McCauley Rod Daniels Yi Pu Lin Victoria Gregory Lynne Whittaker Xiang Zheng Nicholas Castle Johannes Kloess Patrick Collins John Skehel Steve Gamblin Steve Wharton WHO Influenza Network Collaborating Centres National Influenza Centres CNRL Network (EISS/VirGil) HPA, Colindale Maria Zambon Angie Lackenby Sergiy Tokar Irina Leneva
Flu, Avian Flu and emerging aspects (H1N1 resistance)
EU-CIS Seminar New trends in Infectious Diseases 26 28 November 2008 / Lyon, France Flu, Avian Flu and emerging aspects (H1N1 resistance) Pr. Florence MORFIN FRE 3011 Université Lyon 1 - CNRS Laboratory
More informationReview. The antiviral resistance of influenza virus. Vanessa Escuret 1,2, Olivier Ferraris 2 & Bruno Lina 1,2
Review The antiviral resistance of influenza virus The 2009 pandemic confirmed the increasing role antiviral treatment plays in influenza disease management in severe cases. In the 1960s adamantane derivatives
More informationInfluenza surveillance and pandemic preparedness - a global challenge Anne Kelso
Influenza surveillance and pandemic preparedness - a global challenge Anne Kelso WHO Collaborating Centre for Reference and Research on Influenza Melbourne, Australia Three global health challenges 243
More informationTECHNICAL DOCUMENT Community Network of Reference Laboratories (CNRL) for Human Influenza in Europe. Influenza virus characterisation
Community Network of Reference Laboratories (CNRL) for Human Influenza in Europe Influenza virus characterisation Summary Europe, January 2010 A(H1N1pdm) viruses have continued to predominate. Surveillance
More informationEmergence and Fixing of Antiviral Resistance in Influenza A Via Recombination and Hitch Hiking. Henry L Niman
Emergence and Fixing of Antiviral Resistance in Influenza A Via Recombination and Hitch Hiking Henry L Niman Recombinomics, Inc, Pittsburgh, Pennsylvania USA Department of Influenza Recombination Recombinomics,
More informationInfluenza viruses. Virion. Genome. Genes and proteins. Viruses and hosts. Diseases. Distinctive characteristics
Influenza viruses Virion Genome Genes and proteins Viruses and hosts Diseases Distinctive characteristics Virion Enveloped particles, quasi-spherical or filamentous Diameter 80-120 nm Envelope is derived
More informationTREATING MEXICAN (NOVEL) INFLUENZA IN AN IMMUNOCOMPROMISED PATIENT
TREATING MEXICAN (NOVEL) INFLUENZA IN AN IMMUNOCOMPROMISED PATIENT Zanamivir (carbons coloured grey) No conformational change required to allow binding Sialic acid Natural Substrate (carbons coloured
More informationDiagnosing and managing
www.bpac.org.nz keyword: influenza influenza Diagnosing and managing Key reviewers: Associate Professor Mark Thomas, Infectious Disease Specialist, School of Medical Sciences, University of Auckland Dr
More informationSituation Update Pandemic (H1N1) August 2009
Situation Update Pandemic (H1N1) 2009 31 August 2009 Timeline pandemic (H1N1) 2009 April 12: an outbreak of influenza-like illness in Veracruz, Mexico reported to WHO April 15-17: two cases of the new
More informationPublic health relevant virological features of Influenza A(H7N9) causing human infection in China
Public health relevant virological features of Influenza A(H7N9) causing human infection in China Address requests about publications of the WHO Regional Office for Europe to: Publications WHO Regional
More informationPreparing for the Fall Flu Season. Jonathan Gubbay Medical Microbiologist Public Health Laboratory OAHPP
Preparing for the Fall Flu Season Laboratory Perspective Jonathan Gubbay Medical Microbiologist Public Health Laboratory OAHPP September 21, 2009 Objectives 1. Review the emergence of Novel Influenza A
More informationAvian Influenza: Armageddon or Hype? Bryan E. Bledsoe, DO, FACEP The George Washington University Medical Center
Avian Influenza: Armageddon or Hype? Bryan E. Bledsoe, DO, FACEP The George Washington University Medical Center Definitions: Epidemic The occurrence of cases of an illness in a community or region which
More informationReview Influenza virus susceptibility and resistance to oseltamivir
Review Influenza virus susceptibility and resistance to oseltamivir Fred Y Aoki 1, Guy Boivin 2 and Noel Roberts 3 * Antiviral Therapy 12:603 616 1 Department of Medical Microbiology, University of Manitoba,
More informationINFLUENZA VIRUS. INFLUENZA VIRUS CDC WEBSITE
INFLUENZA VIRUS INFLUENZA VIRUS CDC WEBSITE http://www.cdc.gov/ncidod/diseases/flu/fluinfo.htm 1 THE IMPACT OF INFLUENZA Deaths: PANDEMICS 1918-19 S p a n is h flu 5 0 0,0 0 0 U S 2 0,0 0 0,0 0 0 w o rld
More informationNothing to disclose. Influenza Update. Influenza Biology. Influenza Biology. Influenza A 12/15/2014
Influenza Update Nothing to disclose. Lisa Winston, MD UCSF / San Francisco General Hospital Divisions of Infectious Diseases and Hospital Medicine Influenza Biology Influenza Biology Influenza viruses
More informationInfluenza: Seasonal, Avian, and Otherwise
Influenza: Seasonal, Avian, and Otherwise Lisa Winston, MD University of California, San Francisco San Francisco General Hospital Influenza biology Antiviral medications Seasonal influenza Vaccination
More informationQ: If antibody to the NA and HA are protective, why do we continually get epidemics & pandemics of flu?
Influenza virus Influenza virus Orthomyxoviridae family of viruses RNA enveloped viruses that make up three genera Influenzavirus A Influenzavirus B Influenzavirus C The type A viruses are the most virulent
More informationRunning head: INFLUENZA VIRUS SEASON PREPAREDNESS AND RESPONSE 1
Running head: INFLUENZA VIRUS SEASON PREPAREDNESS AND RESPONSE 1 Electron micrograph of H1N1 Virus (CDC, 2009) Influenza Virus Season Preparedness and Response Patricia Bolivar Walden University Epidemiology
More informationAvian Influenza (Bird Flu) Fact Sheet
What is an avian influenza A (H5N1) virus? Influenza A (H5N1) virus also called H5N1 virus is an influenza A virus subtype that occurs mainly in birds. It was first isolated from birds (terns) in South
More informationInfluenza Infection In Human. Dr. Zuhaida A. Jalil Surveillance Sector Disease Control Division, MOH Malaysia 3 May 2018
Influenza Infection In Human Dr. Zuhaida A. Jalil Surveillance Sector Disease Control Division, MOH Malaysia 3 May 2018 Objective of the session: After completing this session, you will be able to: Understand
More informationPandemic Planning Update. Anita L. Barkin, DrPH, MSN, CRNP ACHA Annual Meeting Orlando, Florida 2008
Pandemic Planning Update Anita L. Barkin, DrPH, MSN, CRNP ACHA Annual Meeting Orlando, Florida 2008 Current Status of H5N1 383 human cases (5/29/08) 62% fatality rate Median age 18-20 previously healthy
More informationIncorporating virologic data into seasonal and pandemic influenza vaccines
Incorporating virologic data into seasonal and pandemic influenza vaccines Kanta Subbarao WHO Collaborating Centre for Reference and Research on Influenza & Department of Microbiology and Immunology, University
More informationInfluenza A 6/23/2010. Lisa Winston, MD UCSF / San Francisco General Hospital Divisions of Infectious Diseases and Hospital Medicine
Influenza Update in a Pandemic Year Nothing to disclose. Lisa Winston, MD UCSF / San Francisco General Hospital Divisions of Infectious Diseases and Hospital Medicine Influenza Biology Influenza Biology
More informationPlanning for Respiratory Pandemics. Michael G. Ison, MD MS. Viruses in May
Planning for Respiratory Pandemics Michael G. Ison, MD MS Divisions of Infectious Diseases & Organ Transplantation Transplant Infectious Diseases Service Northwestern University Comprehensive Transplant
More informationEmergence of distinct avian-like influenza A H1N1 viruses in pigs in Ireland and their reassortment with cocirculating H3N2 viruses
International Congress Series 1263 (2004) 209 213 Emergence of distinct avian-like influenza A H1N1 viruses in pigs in Ireland and their reassortment with cocirculating H3N2 viruses Y.P. Lin a, *, M. Bennett
More informationPatricia Fitzgerald-Bocarsly
FLU Patricia Fitzgerald-Bocarsly October 23, 2008 Orthomyxoviruses Orthomyxo virus (ortho = true or correct ) Negative-sense RNA virus (complementary to mrna) Five different genera Influenza A, B, C Thogotovirus
More informationInfluenza Pandemic (H1N1) 2009
Influenza Pandemic (H1N1) 2009 7 th Congress on Communicable Diseases Lisboa 29 January 2010 World Health Organization Overview Since April 2009, first influenza pandemic of 21 st century underway Most
More informationH1N1 influenza pandemic ( Spanish flu ) probably killed million people globally. Seasonal flu can cause ,000 deaths (WHO).
Influenza-1918-2018. Are we ready for another pandemic? 1918-20 H1N1 influenza pandemic ( Spanish flu ) probably killed 50-100 million people globally. Seasonal flu can cause 250-500,000 deaths (WHO).
More informationAntiviral-resistant B viruses with a novel mutation detected by antiviral resistance surveillance in Japan
6thMeeting of NICs in the WPR and SEAR 29-31 May, 2012 Hanoi VN Antiviral-resistant B viruses with a novel mutation detected by antiviral resistance surveillance in Japan Masaki Imai WHO Collaborating
More informationCurrent Vaccines: Progress & Challenges. Influenza Vaccine what are the challenges?
Current Vaccines: Progress & Challenges Influenza Vaccine what are the challenges? Professor John S. Tam The Hong Kong Polytechnic University Asia-Pacific Alliance for the Control of Influenza (APACI)
More informationProtein Modeling Event
Protein Modeling Event School Name: School Number: Team Member 1: Team Member 2: : Pre-Build Score: On-Site Build Score: Test Score: Tie Breaker: Total: Final Rank: Part I: Pre-Build (40% of total score)
More informationEmerging Infections: Pandemic Influenza. W. Paul Glezen
Emerging Infections: Pandemic Influenza W. Paul Glezen Challenges The trends of modern society tend to facilitate spread and increase morbidity Travel, urbanization morbidity vs. mortality The cost of
More informationThe "Flu" a case of low fever and sniffles that keeps you home in bed for a day a gastrointestinal upset ("stomach flu")
The "Flu" Influenza is a viral infection of the lungs characterized by fever, cough, and severe muscle aches. In the elderly and infirm, it is a major cause of disability and death (often as a result of
More informationUnderstanding mortality from pandemic and seasonal influenza
Understanding mortality from pandemic and seasonal influenza Jonathan A. McCullers Associate Member Department of Infectious Diseases St. Jude Children s Research Hospital H1 H2 H3 H4 H5 H6 H7 H8 H9 H10
More informationInfluenza virus.
INFLUENZA VIRUS Adapté en partie des exposés de la Chaire Franqui 2003 "Antiviral drugs and Discoveries in Medicine" Prof. E. De Clercq, KU-Leuven http://www.md.ucl.ac.be/chaire-francqui/ Influenza virus
More informationThe A(H7N9) influenza outbreak in China
Viruses in May, Katoomba, 9 11 May 2013 The A(H7N9) influenza outbreak in China Anne Kelso Director WHO Collaborating Centre for Reference and Research on Influenza Melbourne Influenza in the 21 st century:
More informationInfluenza virus.
INFLUENZA VIRUS Adapté en partie des exposés de la Chaire Franqui 2003 "Antiviral drugs and Discoveries in Medicine" Prof. E. De Clercq, KU-Leuven http://www.md.ucl.ac.be/chaire-francqui/ et de l'exposé
More informationInfluenza. Paul K. S. Chan Department of Microbiology The Chinese University of Hong Kong
Influenza Paul K. S. Chan Department of Microbiology The Chinese University of Hong Kong Influenza Virus Nomenclature Influenza virus A, B & C Influenza A : Haemagglutinin (H), neuraminidase (N) A H3N2,
More informationEvolution of influenza
Evolution of influenza Today: 1. Global health impact of flu - why should we care? 2. - what are the components of the virus and how do they change? 3. Where does influenza come from? - are there animal
More informationTable 1. Frequency of resistant viruses isolated in Japan during 2007/2008 influenza season.
Preliminary summary on oseltamivir-resistant H1N1 virus: Japan Reporting date: 9 May 2008 During the 2007/2008 Northern Hemisphere influenza season in Japan, a total of 1,360 H1N1 viruses have been tested
More informationVIROLOGY OF INFLUENZA. Subtypes: A - Causes outbreak B - Causes outbreaks C - Does not cause outbreaks
INFLUENZA VIROLOGY OF INFLUENZA Subtypes: A - Causes outbreak B - Causes outbreaks C - Does not cause outbreaks PATHOGENICITY High pathogenicity avian influenza (HPAI) Causes severe disease in poultry
More informationInfluenza. Tim Uyeki MD, MPH, MPP, FAAP
Influenza Tim Uyeki MD, MPH, MPP, FAAP Influenza Division National Center for Immunization and Respiratory Diseases Coordinating Center for Infectious Diseases Centers for Disease Control and Prevention
More informationOrthomyxoviridae and Paramyxoviridae. Lecture in Microbiology for medical and dental medical students
Orthomyxoviridae and Paramyxoviridae Lecture in Microbiology for medical and dental medical students Orthomyxoviridae and Paramyxoviridae are ss RNA containng viruses Insert Table 25.1 RNA viruses 2 SIZE
More information1918 Influenza; Influenza A, H1N1. Basic agent information. Section I- Infectious Agent. Section II- Dissemination
1918 Influenza; Influenza A, H1N1 Basic agent information Section I- Infectious Agent Risk Group: - RG3 Synonym or Cross reference: - Spanish Flu - 1918 Flu - El Grippe Characteristics: - SELECT AGENT
More informationSummary. Primary care data. Week 49/2014. Season
Summary Week 49/2014 In week 49/2014, influenza activity remained low across the WHO European Region. Twenty countries reported sporadic influenza activity and nine reported increasing trends in consultations
More informationHuman Cases of Swine Influenza in California, Kansas, New York City, Ohio, Texas, and Mexico Key Points April 26, 2009
1 Today, CDC confirmed additional human cases of swine influenza A (H1N1) virus infection in the United States, bringing the total number of U.S. confirmed cases to 21. This includes cases in California,
More informationRecommended composition of influenza virus vaccines for use in the influenza season
Recommended composition of influenza virus vaccines for use in the 2009 2010 influenza season February 2009 This recommendation relates to the composition of vaccines for the forthcoming influenza season
More informationORTHOMYXOVIRUSES INFLUENZA VIRUSES. (A,B and C)
ORTHOMYXOVIRUSES INFLUENZA VIRUSES (A,B and C) Orthomyxoviridae Influenza Viruses Epidemiology: Influenza A virus is so subjected to major antigenic changes that cause occasional world wide pandemics when
More informationSummary. Week 13/2018 (26 31 March 2018) season overview
Summary Week 13/2018 (26 31 March 2018) Influenza viruses continued to circulate in the Region, while all countries reported low or medium intensity of activity of respiratory infections. Influenza continued
More informationInfluenza. Paul K. S. Chan Department of Microbiology The Chinese University of Hong Kong
Influenza Paul K. S. Chan Department of Microbiology The Chinese University of Hong Kong Classification & Nomenclature Influenza virus A, B & C Influenza A : Haemagglutinin (H 1-16), neuraminidase (N1-9)
More informationInfluenza and other Respiratory Viruses Update
Influenza and other Respiratory Viruses Update-- 2017 Pete Shult, PhD CDD Director & Emergency Laboratory Response and Erik Reisdorf, MPH, M(ASCP) CM Surveillance and Virology Lab-Team Lead WISCONSIN STATE
More informationISPUB.COM. Bird flu: A Throbbing Stone In An Infectious Era. T Wadhwa, P Kumar Thirupathi EPIDEMIOLOGY TRANSMISSION FROM AVIAN TO HUMAN
ISPUB.COM The Internet Journal of Infectious Diseases Volume 7 Number 1 T Wadhwa, P Kumar Thirupathi Citation T Wadhwa, P Kumar Thirupathi.. The Internet Journal of Infectious Diseases. 2008 Volume 7 Number
More information6.2 Pandemic influenza
6.2 Pandemic influenza See Background Paper 6.2 (BP6_2Pandemic.pdf) Background and developments since 2004 The WHO estimates that annual influenza epidemics account for about 3 to 5 million cases of severe
More informationSummary. Week 15/2018 (9 15 April 2018) season overview
Summary Week 15/2018 (9 15 April 2018) Influenza viruses continued to circulate in the Region with 26% of the individuals sampled from primary healthcare settings testing positive, while all countries
More informationInfluenza: The past, the present, the (future) pandemic
Influenza: The past, the present, the (future) pandemic Kristin Butler, MLS (ASCP) cm Department of Clinical Laboratory Sciences Louisiana Health Sciences Center - Shreveport Fall 2017 Objectives 1) Detail
More informationDevelopment of an Influenza Risk Assessment Tool
Development of an Influenza Risk Assessment Tool Susan C. Trock, DVM, MPH, Dip. ACVPM (Epi) Influenza Division, NCIRD, CDC OFFLU Technical Meeting, April 5, 2012 National Center for Immunization & Respiratory
More informationProphylaxis and Treatment for Influenza among the Elderly
Respiratory Diseases in the Elderly Prophylaxis and Treatment for Influenza among the Elderly JMAJ 45(6): 245 250, 2002 Hajime GOTO Professor, The First Department of Internal Medicine, Kyorin University
More informationPandemic Influenza influenza epidemic: realization of a worst-case scenario
Pandemic Influenza October 9, 2006 1918 influenza epidemic: realization of a worst-case scenario First case: Albert Mitchell, Camp Funston, KS, March 11, 1918 Up to 20% of all humans infected 20-50 million
More informationTECHNICAL DOCUMENT. Influenza virus characterisation. Influenza A(H3N2) virus analysis. Summary Europe, December Summary
Community Network of Reference Laboratories (CNRL) for Human Influenza in Europe Influenza virus characterisation Summary Europe, December 2011 Summary Since week 40/2011, influenza A(H1N1)pdm09, influenza
More informationAvian influenza Avian influenza ("bird flu") and the significance of its transmission to humans
15 January 2004 Avian influenza Avian influenza ("bird flu") and the significance of its transmission to humans The disease in birds: impact and control measures Avian influenza is an infectious disease
More informationNASDAQ:NVAX Novavax, Inc. All rights reserved.
Novavax vaccine induced improved immune responses against homologous and drifted A(H3N2) viruses in older adults compared to egg-based, high-dose, influenza vaccine World Vaccine Congress April 4, 2018
More informationQuestions and Answers
Questions and Answers Recommended composition of influenza virus vaccines for use in the southern hemisphere 2016 influenza season and development of candidate vaccine viruses for pandemic preparedness
More informationLesson 20 Study Guide: Medical Biotechnology Pandemic Flu & Emergent Disease
URI CMB 190 Issues in Biotechnology Lesson 20 Study Guide: Medical Biotechnology Pandemic Flu & Emergent Disease 1. The film Contagion: (A) entirely depicts a situation that could never possibly happen
More informationECDC TECHNICAL REPORT
TECHNICAL REPORT External quality assessment scheme for antiviral susceptibility detection in influenza viruses for the Community Network of Reference Laboratories for Human Influenza in Europe 2010/2011
More informationIntroduction to Avian Influenza
Introduction to Avian Influenza David L. Suarez D.V.M., Ph.D. Research Leader Exotic and Emerging Avian Viral Disease Research Unit Agricultural Research Service United States Department of Agriculture
More informationConflict of Interest and Disclosures. Research funding from GSK, Biofire
Pandemic Influenza Suchitra Rao, MBBS, Assistant Professor, Pediatric Infectious Diseases, Hospital Medicine and Epidemiology Global Health and Disasters Course, 2018 Conflict of Interest and Disclosures
More informationINFLUENZA VIRUS. Influenza virus
IFLUEZA VIRUS Adapté en partie des exposés de la Chaire Franqui 2003 "Antiviral drugs and Discoveries in Medicine" Prof. E. De Clercq, KU-Leuven http://www.md.ucl.ac.be/chaire-francqui/ Influenza virus
More informationLive Attenuated Influenza Vaccine. I. Background and Seasonal Vaccine
Live Attenuated Influenza Vaccine I. Background and Seasonal Vaccine Influenza infection stimulates multiple arms of the immune system Systemic antibody to HA and NA, and multiple internal proteins Mucosal
More informationRecommended composition of influenza virus vaccines for use in the 2009 southern hemisphere influenza season
Recommended composition of influenza virus vaccines for use in the 2009 southern hemisphere influenza season The World Health Organization (WHO) convenes technical meetings 1 in February and September
More informationGlobal Pandemic Preparedness Research Efforts. Klaus Stöhr. WHO Global Influenza Programme. Today
Global Pandemic Preparedness Research Efforts Klaus Stöhr 3 Today Medium-term applied research linked to medical and public health interventions addressing the current pandemic situation in Asia Natural
More informationSwine Influenza A: Information for Child Care Providers INTERIM DAYCARE ADVISORY General Information: do not
Swine Influenza A: Information for Child Care Providers INTERIM DAYCARE ADVISORY 4-29-2009 The State of Connecticut Department of Public Health (DPH) would like to provide information to childcare providers
More informationEmergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir
BRIEF REPORT Emergence of Multidrug-Resistant Influenza A(H1N1)pdm09 Virus Variants in an Immunocompromised Child Treated With Oseltamivir and Zanamivir Daisuke Tamura, 1,a Roberta L. DeBiasi, 2,4,5,a
More informationCurrent CEIRS Program
History The influenza program at St. Jude has a long, distinguished history as a world-class leader in the study of the origins, evolution, and pathogenesis of influenza viruses. Based on this expertise,
More informationGlobal Influenza Virus Surveillance and WHO Influenza Vaccine Virus Recommendations for the Northern Hemisphere Influenza Season
Global Influenza Virus Surveillance and WHO Influenza Vaccine Virus Recommendations for the Northern Hemisphere 2015-16 Influenza Season Jacqueline Katz, Ph. D. Deputy Director (acting), Influenza Division
More informationPandemic preparedness in Europe
Pandemic preparedness in Europe Ted van Essen, University Medical Center Utrecht, The Netherlands Science Policy Flu Summit, Brussels, 30 September 2015 Recent avian influenza virus outbreaks are a strong
More informationThe Need for Linking with Public Health
The Need for Linking with Public Health Xiyan Xu MD, MS Influenza Branch Division of Viral and Rickettsial Diseases National Center for Infectious Diseases Centers for Disease Control and Prevention Key
More informationInfluenza Global Epidemiologic Update
Influenza Global Epidemiologic Update November 10 th, 2017 1. GLOBAL WHO SUMMARY based on data up to 15 October 2017 North America: Overall influenza virus activity remained low, with detections of predominantly
More informationDetection and management of antiviral resistance for influenza viruses
DOI:10.1111/irv.12176 www.influenzajournal.com Review Article Detection and management of antiviral resistance for influenza viruses Guy Boivin CHUQ-CHUL and Laval University, Quebec, QC, Canada. Correspondence:
More informationC~ 6 D~~J ~ old ~ s rw~ o, - _ - 2 DEPARTMENT OF HEALTH AND HUMAN SERVICES. Food and Drug Administration. 21 CFR Part 530
DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration 21 CFR Part 530, s rw~ o, - _ - 2 [Docket No. 2006N-0106] New Animal Drugs ; Adamantane and Neuraminidase Inhibitor Anti-influenza Drugs
More informationLECTURE OUTLINE. B. AGENT: Varicella-zoster virus. Human herpes virus 3. DNA virus.
Viral Vaccines II LECTURE OUTLINE 5/24/04 I. CASE HISTORY A 5-year old comes home from school with a red skin rash on his chest that spreads to over 300 itchy blisters that spread further to his face,
More informationDesign and antiviral properties of influenza virus neuraminidase inhibitors
Pure & Appl. Chem., Vol. 67, No. 1, pp. 1683-1688, 1995. Printed in Great Britain. ( 1995 IUPAC Design and antiviral properties of influenza virus neuraminidase inhibitors P. M. Colman Biomolecular Research
More informationInfluenza A H1N1 (Swine Flu 2009) Hemagglutinin / HA ELISA Pair Set
Influenza A H1N1 (Swine Flu 2009) Hemagglutinin / HA ELISA Pair Set Catalog Number : SEK001 To achieve the best assay results, this manual must be read carefully before using this product and the assay
More informationINFLUENZA. Rob Young (James. J. Reid) Faculty of Medicine University of Auckland (Otago)
INFLUENZA Rob Young (James. J. Reid) Faculty of Medicine University of Auckland (Otago) INFLUENZA Don t confuse with the common cold Symptoms may be similar BUT those with influenza are sick those with
More informationGlobal Challenges of Pandemic and Avian Influenza. 19 December 2006 Keiji Fukuda Global influenza Programme
Global Challenges of Pandemic and Avian Influenza 19 December 2006 Keiji Fukuda Global influenza Programme Summary of Current H5N1 Situation 1997 First known outbreak infecting humans 18 people hospitalized
More informationShould the U.S. develop and stockpile vaccines against A(H5N1) avian flu?
Amy Dewees July 7, 2006 Biol 501 Should the U.S. develop and stockpile vaccines against A(H5N1) avian flu? A(H5N1) is a strain of flu virus that infects many species of birds, including domestic and migratory
More informationREPORT. Early risk assessment: What to expect of the 2017/18 influenza season in Norway
2017 REPORT Early risk assessment: What to expect of the 2017/18 influenza season in Norway Early risk assessment: What to expect of the 2017/18 influenza season in Norway Department of Influenza 2 Published
More informationINFLUENZA-2 Avian Influenza
INFLUENZA-2 Avian Influenza VL 7 Dec. 9 th 2013 Mohammed El-Khateeb Overview 1. Background Information 2. Origin/History 3. Brief overview of genome structure 4. Geographical Distribution 5. Pandemic Nature
More informationGuidelines for clinical management of severe influenza infection. Aeron Hurt
Guidelines for clinical management of severe influenza infection Aeron Hurt Current WHO guidelines WHO guidance documents for the clinical management of influenza virus infection were published in 2007
More informationAVIAN FLU BACKGROUND ABOUT THE CAUSE. 2. Is this a form of SARS? No. SARS is caused by a Coronavirus, not an influenza virus.
AVIAN FLU BACKGROUND 1. What is Avian Influenza? Is there only one type of avian flu? Avian influenza, or "bird flu", is a contagious disease of animals caused by Type A flu viruses that normally infect
More informationUNIVERSAL INFLUENZA VIRUS VACCINES Adolfo García Sastre. Icahn School of Medicine at Mount Sinai, New York
UNIVERSAL INFLUENZA VIRUS VACCINES Adolfo García Sastre Icahn School of Medicine at Mount Sinai, New York INFLUENZA VIRUSES PAx B EPIDEMIOLOGY OF HUMAN INFLUENZA VIRUSES A H1N1 H3N2 1968 H2N2 1957 H1N1
More informationTexas Influenza Summary Report, Season (September 28, 2008 April 11, 2009)
Texas Influenza Summary Report, 2008 2009 Season (September 28, 2008 April 11, 2009) Background Influenza and influenza-like illnesses (ILI) were last reportable by law in any county in Texas in 1993 (1).
More informationInfluenza A virus subtype H5N1
Influenza A virus subtype H5N1 Influenza A virus subtype H5N1, also known as A(H5N1) or simply H5N1, is a subtype of the Influenza A virus which can cause illness in humans and many other animal species.
More informationAn Exploration to Determine if Fab Molecules are Efficacious in Neutralizing Influenza H1 and H3 Subtypes. Nick Poulton June September 2012
An Exploration to Determine if Fab Molecules are Efficacious in Neutralizing Influenza H1 and H3 Subtypes Nick Poulton June 2012- September 2012 Epidemiology of Influenza Infection Causes between 250,000
More informationInfluenza: The Threat of a Pandemic
April, 2009 Definitions Epidemic: An increase in disease above what you what would normally expect. Pandemic: A worldwide epidemic 2 What is Influenza? Also called Flu, it is a contagious respiratory illness
More informationWISCONSIN STATE LABORATORY OF HYGIENE - UNIVERSITY OF WISCONSIN 6 WISCONSIN STATE LABORATORY OF HYGIENE - UNIVERSITY OF WISCONSIN 8
Influenza and other Respiratory Viruses Update-- 2018 Pete Shult, PhD CDD Director & Emergency Laboratory Response and Erik Reisdorf, MPH, M(ASCP) CM Surveillance and Virology Lab-Team Lead Learning Objectives
More informationRalph KY Lee Honorary Secretary HKIOEH
HKIOEH Round Table: Updates on Human Swine Influenza Facts and Strategies on Disease Control & Prevention in Occupational Hygiene Perspectives 9 July 2009 Ralph KY Lee Honorary Secretary HKIOEH 1 Influenza
More informationWORLD HEALTH ORGANIZATION
WORLD HEALTH ORGANIZATION FIFTY-NINTH WORLD HEALTH ASSEMBLY A59/4 Provisional agenda item 11.1 24 April 2006 Strengthening pandemic-influenza preparedness and response, including application of the International
More informationAI/PI UPDATE. September 2007 Defense Health Board
AI/PI UPDATE September 2007 Defense Health Board LTC Wayne E. Hachey DO, MPH Office of the Assistant Secretary of Defense (Health Affairs) Force Health Protection & Readiness PP0066 H5N1 Avian Influenza
More informationAntivirals for Avian Influenza Outbreaks
Antivirals for Avian Influenza Outbreaks Issues in Influenza Pandemic Preparedness 1. Surveillance for pandemic preparedness eg. H5N1 2. Public health intervention eg. efficacy, feasibility and impact
More informationInfluenza Updates Reflection on 2017: thank you and happy holidays
Influenza Updates The newsletter of the WHO Collaborating Centre for Reference and Research on Influenza in Melbourne Volume 6, Issue 3, November 2017 Reflection on 2017: thank you and happy holidays As
More information